

# Richard M Camicioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8606801/publications.pdf>

Version: 2024-02-01

175  
papers

9,741  
citations

36303

51  
h-index

43889

91  
g-index

183  
all docs

183  
docs citations

183  
times ranked

12436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediators of cognitive impairment in cerebral amyloid angiopathy. International Journal of Stroke, 2023, 18, 78-84.	5.9	7
2	Diffusion tensor tractography of the fornix in cerebral amyloid angiopathy, mild cognitive impairment and Alzheimer's disease. Neurolmage: Clinical, 2022, 34, 103002.	2.7	2
3	Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy. Neurology, 2022, 98, .	1.1	14
4	Dual-task gait and mild behavioral impairment: The interface between non-cognitive dementia markers. Experimental Gerontology, 2022, 162, 111743.	2.8	10
5	Multi sequence average templates for aging and neurodegenerative disease populations. Scientific Data, 2022, 9, .	5.3	5
6	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12235.	2.4	6
7	Vascular Contributions to Neurodegeneration: Protocol of the COMPASS-ND Study. Canadian Journal of Neurological Sciences, 2021, , 1-8.	0.5	6
8	Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. Alzheimer's and Dementia, 2021, 17, 1317-1328.	0.8	79
9	Beware of white matter hyperintensities causing systematic errors in <scp>FreeSurfer</scp> gray matter segmentations!. Human Brain Mapping, 2021, 42, 2734-2745.	3.6	26
10	The role of physical exercise in modulating peripheral inflammatory and neurotrophic biomarkers in older adults: A systematic review and meta-analysis. Mechanisms of Ageing and Development, 2021, 194, 111431.	4.6	15
11	White matter hyperintensities mediate the impact of amyloid Aβ on future freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 85, 95-101.	2.2	12
12	New horizons in falls prevention and management for older adults: a global initiative. Age and Ageing, 2021, 50, 1499-1507.	1.6	50
13	Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning. Movement Disorders, 2021, 36, 2144-2155.	3.9	40
14	Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 111-118.	2.2	9
15	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.1	14
16	White matter hyperintensities in patients with Parkinson's disease: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2021, 426, 117481.	0.6	19
17	Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson's Disease. Journal of Proteome Research, 2021, 20, 4053-4067.	3.7	14
18	The Trajectory of Motor Deterioration to Death in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 670567.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Cerebral Amyloid Angiopathy Is Associated With Emotional Dysregulation, Impulse Dyscontrol, and Apathy. <i>Journal of the American Heart Association</i> , 2021, 10, e022089.	3.7	9
20	Evaluation of Clinical Practice Guidelines on Fall Prevention and Management for Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2138911.	5.9	121
21	Falls in Synucleinopathies. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 30-43.	0.5	7
22	Mapping Associations Between Gait Decline and Fall Risk in Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 576-584.	2.6	20
23	The Effects of Music-Contingent Gait Training on Cognition and Mood in Parkinson Disease: A Feasibility Study. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 82-92.	2.9	17
24	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.8	119
25	Cognitive and motor correlates of grey and white matter pathology in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 27, 102353.	2.7	36
26	CCCDT5 recommendations on early non cognitive markers of dementia: A Canadian consensus. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12068.	3.7	29
27	The associations of the BDNF and APOE polymorphisms, hippocampal subfield volumes, and episodic memory performance across the lifespan. <i>Hippocampus</i> , 2020, 30, 1081-1097.	1.9	4
28	Dual decline in gait speed and cognition is associated with future dementia: evidence for a phenotype. <i>Age and Ageing</i> , 2020, 49, 995-1002.	1.6	32
29	Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 246-251.	1.7	6
30	Can osmotic demyelination syndrome be a complication of liver failure?. <i>ENeurologicalSci</i> , 2020, 18, 100223.	1.3	2
31	Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis?. <i>JAMA Neurology</i> , 2020, 77, 393.	9.0	7
32	Falls in Parkinson's Disease and Lewy Body Dementia. , 2020, , 191-210.		1
33	Falls as a Manifestation of Brain Failure: Gait, Cognition, and the Neurobiology of Falls. , 2020, , 3-20.		3
34	Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 897-909.	3.6	125
35	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.5	56
36	<p>Orthostatic hypotension and dementia incidence: links and implications</p>Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2181-2194.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Physical Activity and Mobility Differentially Predict Nondemented Executive Function Trajectories: Do Sex and &lt;b&gt;&lt;i&gt;APOE&lt;/i&gt;&lt;/b&gt; Moderate These Associations?. <i>Gerontology</i> , 2019, 65, 640-648.	2.8	6
38	Gait impairments in Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 697-708.	10.2	374
39	Management of Cerebral Microbleeds in Clinical Practice. <i>Translational Stroke Research</i> , 2019, 10, 449-457.	4.2	14
40	Progressive Supranuclear Palsy-like Syndrome from Possible Cerebral Amyloid Angiopathy. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 132-136.	0.5	2
41	Cognitive profile of non-demented Parkinson's disease: Meta-analysis of domain and sex-specific deficits. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 32-42.	2.2	26
42	Amygdala subnuclei and healthy cognitive aging. <i>Human Brain Mapping</i> , 2019, 40, 34-52.	3.6	12
43	Frailty Prevalence in the COMPASS-ND Study of Neurodegenerative Disorders. <i>Canadian Geriatrics Journal</i> , 2019, 22, 205-212.	1.2	8
44	Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms clarification letter. <i>International Psychogeriatrics</i> , 2018, 30, 1417-1417.	1.0	0
45	The association between lower urinary tract symptoms and falls: Forming a theoretical model for a research agenda. <i>Neurourology and Urodynamics</i> , 2018, 37, 501-509.	1.5	66
46	Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic and the Development of a New Screening Strategy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 153-161.	1.6	3
47	Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms. <i>International Psychogeriatrics</i> , 2018, 30, 253-260.	1.0	24
48	Nonmotor Symptoms of Parkinsonâ€™s Disease as Predictors of Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 97-99.	0.5	10
49	Guidelines for Gait Assessments in the Canadian Consortium on Neurodegeneration in Aging (CCNA). <i>Canadian Geriatrics Journal</i> , 2018, 21, 157-165.	1.2	43
50	Alzheimerâ€™s Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 296.	3.4	25
51	Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1401-1416.	2.6	62
52	Differentiating cognitive or motor dimensions associated with the perception of fall-related self-efficacy in Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 26.	5.3	9
53	Cognitive impairment in Parkinsonâ€™s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110
54	SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment. <i>BMC Geriatrics</i> , 2018, 18, 93.	2.7	45

#	ARTICLE	IF	CITATIONS
55	Utility of the Addenbrooke's Cognitive Examination in Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2018, 45, 527-532.	0.5	5
56	Alzheimer's disease: typical and atypical. Part 1. Shidno-Svopejskij Zhurnal Hvrobi Parkinsona J Ekstraparam-dnih Zahvorovan <sup>1</sup> , 2018, 4, 3-9.	0.0	0
57	Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment. JAMA Neurology, 2017, 74, 857.	9.0	263
58	Intensive intervention and cognitive impairment. Neurology, 2017, 88, 1984-1985.	1.1	0
59	Evolution of deep gray matter volume across the human lifespan. Human Brain Mapping, 2017, 38, 3771-3790.	3.6	115
60	Decisional capacity for advanced care directives in Parkinson's disease with cognitive concerns. Parkinsonism and Related Disorders, 2017, 39, 77-79.	2.2	31
61	Regional volumetric change in Parkinson's disease with cognitive decline. Journal of the Neurological Sciences, 2017, 373, 88-94.	0.6	24
62	Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis. Movement Disorders, 2017, 32, 1720-1728.	3.9	69
63	White matter hyperintensity volume predicts persistent cognitive impairment in transient ischemic attack and minor stroke. International Journal of Stroke, 2017, 12, 264-272.	5.9	34
64	Neurological Nuance: Hodgkin lymphoma presenting with Guillain-Barré syndrome. Muscle and Nerve, 2017, 55, 601-604.	2.2	7
65	Alzheimer's Disease Biomarkers Interactively Influence Physical Activity, Mobility, and Cognition Associations in a Non-Demented Aging Population. Journal of Alzheimer's Disease, 2017, 60, 69-86.	2.6	14
66	Concurrent Indicators of Gait Velocity and Variability Are Associated with 25-Year Cognitive Change: A Retrospective Longitudinal Investigation. Frontiers in Aging Neuroscience, 2017, 9, 17.	3.4	19
67	Guidelines for Assessment of Gait and Reference Values for Spatiotemporal Gait Parameters in Older Adults: The Biomathics and Canadian Gait Consortiums Initiative. Frontiers in Human Neuroscience, 2017, 11, 353.	2.0	116
68	Early-onset parkinsonism induced by pallidal deep brain stimulation in cervical dystonia. Parkinsonism and Related Disorders, 2016, 29, 140-142.	2.2	3
69	Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype. Canadian Journal of Neurological Sciences, 2016, 43, 261-267.	0.5	46
70	Vascular gait disorders. Neurology, 2016, 86, 1177-1178.	1.1	2
71	Aging, the Central Nervous System, and Mobility in Older Adults: Interventions. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1451-1458.	3.6	29
72	Disentangling Cognitive-Frailty: Results From the Gait and Brain Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1476-1482.	3.6	125

#	ARTICLE	IF	CITATIONS
73	Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 2016, 361, 87-91.	0.6	17
74	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162
75	Handwriting and pre-frailty in the Lausanne cohort 65+ (Lc65+) study. <i>Archives of Gerontology and Geriatrics</i> , 2015, 61, 8-13.	3.0	15
76	Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 351, 127-132.	0.6	6
77	Physical activity, white matter hyperintensities, and motor function: Bringing out the reserves. <i>Neurology</i> , 2015, 84, 1288-1289.	1.1	3
78	Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition Workshop. <i>Canadian Geriatrics Journal</i> , 2015, 18, 159-167.	1.2	34
79	Response to Letter Regarding Article, "Serial Montreal Cognitive Assessments Demonstrate Reversible Cognitive Impairment in Patients With Acute Transient Ischemic Attack and Minor Stroke" Stroke, 2014, 45, e194.	2.0	0
80	Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 368-374.	3.9	17
81	Motoric cognitive risk syndrome. <i>Neurology</i> , 2014, 83, 718-726.	1.1	345
82	Vitamin D and white matter abnormalities in older adults: a cross-sectional neuroimaging study. <i>European Journal of Neurology</i> , 2014, 21, 1436.	3.3	42
83	Serial Montreal Cognitive Assessments Demonstrate Reversible Cognitive Impairment in Patients With Acute Transient Ischemic Attack and Minor Stroke. <i>Stroke</i> , 2014, 45, 1709-1715.	2.0	72
84	Sleep-related breathing disorders and gait variability: a cross-sectional preliminary study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 140.	2.0	14
85	Reply. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 125-130.	1.3	0
86	Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 303-313.	0.5	4
87	Aging, the Central Nervous System, and Mobility. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 1379-1386.	3.6	213
88	Comment: Brain amyloid increases the risk of falls. <i>Neurology</i> , 2013, 81, 441-441.	1.1	3
89	Source memory in normal aging and Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 179-192.	1.4	10
90	Neurocognitive Speed and Inconsistency in Parkinson's Disease with and without Incipient Dementia: An 18-Month Prospective Cohort Study. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 764-772.	1.8	21

#	ARTICLE	IF	CITATIONS
91	Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 546-572.	1.3	42
92	Mild cognitive impairment is associated with selected functional markers: Integrating concurrent, longitudinal, and stability effects.. <i>Neuropsychology</i> , 2012, 26, 209-223.	1.3	35
93	Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-term Study <sup>1</sup> . <i>Movement Disorders</i> , 2012, 27, 1513-1521.	3.9	62
94	Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2012, 79, 1499-1506.	1.1	147
95	Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 809-813.	2.2	74
96	Diffusion tensor imaging of white matter tract evolution over the lifespan. <i>NeuroImage</i> , 2012, 60, 340-352.	4.2	924
97	A reversible cerebral vasoconstriction syndrome. <i>BMJ Case Reports</i> , 2012, 2012, bcr0920114841-bcr0920114841.	0.5	14
98	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 61-75.	2.6	125
99	Structural organization of the prefrontal white matter pathways in the adult and aging brain measured by diffusion tensor imaging. <i>Brain Structure and Function</i> , 2011, 216, 417-431.	2.3	30
100	If amyloid is not in the spinal fluid in Parkinson's disease, where is it and what does it do?. <i>Movement Disorders</i> , 2011, 26, 5-5.	3.9	5
101	Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. <i>Movement Disorders</i> , 2011, 26, 1443-1450.	3.9	56
102	Metabotropic glutamate receptors-mGluR5-new kid on the dissecting block?. <i>Movement Disorders</i> , 2011, 26, 2479-2479.	3.9	0
103	Othello syndrome <sup>at</sup> the interface of neurology and psychiatry. <i>Nature Reviews Neurology</i> , 2011, 7, 477-478.	10.1	10
104	Mesial Prefrontal Cortex Degeneration in Amyotrophic Lateral Sclerosis: A High-Field Proton MR Spectroscopy Study. <i>American Journal of Neuroradiology</i> , 2011, 32, 1677-1680.	2.4	18
105	Corpus Callosum and Cingulum Tractography in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 595-600.	0.5	47
106	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2501-2507.	3.9	155
107	Selective effects of aging on brain white matter microstructure: A diffusion tensor imaging tractography study. <i>NeuroImage</i> , 2010, 52, 1190-1201.	4.2	134
108	Relationship between mild cognitive impairment and falls in older people with and without Parkinson's disease: 1-Year Prospective Cohort Study. <i>Gait and Posture</i> , 2010, 32, 87-91.	1.4	88

#	ARTICLE	IF	CITATIONS
109	Dementia Diagnosis. , 2010, , 385-391.		1
110	Circulating Endothelial Progenitor Cells and Age-Related White Matter Changes. Stroke, 2009, 40, 3191-3196.	2.0	37
111	Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Movement Disorders, 2009, 24, 176-182.	3.9	40
112	The course of depressive symptoms in early Parkinson's disease. Movement Disorders, 2009, 24, 1306-1311.	3.9	43
113	Temporal lobe changes in early, untreated Parkinson's disease. Movement Disorders, 2009, 24, 1949-1954.	3.9	67
114	Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism and Related Disorders, 2009, 15, 187-195.	2.2	82
115	Gaps in patient care practices to prevent hospital-acquired delirium. Canadian Family Physician, 2009, 55, e41-6.	0.4	7
116	Intact presupplementary motor area function in early, untreated Parkinson's disease. Movement Disorders, 2008, 23, 1756-1759.	3.9	5
117	Early, untreated Parkinson's disease patients show reaction time variability. Neuroscience Letters, 2008, 441, 77-80.	2.1	41
118	Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiology of Aging, 2008, 29, 1027-1039.	3.1	146
119	Motor Cortex and Spinal Degeneration in Multisystem Atrophy: A Multimodal Study. Canadian Journal of Neurological Sciences, 2008, 35, 658-660.	0.5	1
120	Aging hippocampus and amygdala. NeuroReport, 2008, 19, 543-547.	1.2	64
121	Review of Handbook of Parkinson's Disease. Fourth Edition. 2007. Edited by Rajesh Pahwa, Kelly E. Lyons. Published by Informa Health Care. 500 pages. Price C\$245.. Canadian Journal of Neurological Sciences, 2008, 35, 687-688.	0.5	0
122	Progressive slowing and gait disorder. , 2008, , 35-38.		0
123	Gait and Balance. , 2007, , 327-342.		1
124	The impact of depressive symptoms in early Parkinson disease. Neurology, 2007, 69, 342-347.	1.1	278
125	Clinical correlates of Lewy-body-related disorders: splitting and lumping or lumping and splitting?. Nature Clinical Practice Neurology, 2007, 3, 308-309.	2.5	0
126	Clinical Trials in Parkinson's Disease Dementia and Dementia with Lewy Bodies. Canadian Journal of Neurological Sciences, 2007, 34, S109-S117.	0.5	7



#	ARTICLE	IF	CITATIONS
127	Axial Signs and Magnetic Resonance Imaging Correlates in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2007, 34, 56-61.	0.5	40
128	Toward a revision of criteria for the dementias. , 2007, 3, 428-440.		15
129	R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Movement Disorders, 2007, 22, 254-256.	3.9	8
130	Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Movement Disorders, 2007, 22, 382-386.	3.9	42
131	SIMPLE COGNITIVE TESTING (MINI-COG) PREDICTS IN-HOSPITAL DELIRIUM IN THE ELDERLY. Journal of the American Geriatrics Society, 2007, 55, 314-316.	2.6	29
132	DEPRESSIVE SYMPTOMS AND COGNITIVE STATUS AFFECT HEALTH-RELATED QUALITY OF LIFE IN OLDER PATIENTS WITH PARKINSON'S DISEASE. Journal of the American Geriatrics Society, 2007, 55, 1888-1890.	2.6	16
133	Three-dimensional volumetric analysis and reconstruction of amygdala and hippocampal head, body and tail. Psychiatry Research - Neuroimaging, 2007, 155, 155-165.	1.8	110
134	Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults. Neuropsychologia, 2007, 45, 2499-2507.	1.6	86
135	Gait and posture impairment, parkinsonism and cognitive decline in older people. Journal of Neural Transmission, 2007, 114, 1355-1361.	2.8	40
136	Dual-tasks and walking fast: Relationship to extra-pyramidal signs in advanced Alzheimer disease. Journal of the Neurological Sciences, 2006, 248, 205-209.	0.6	47
137	Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Movement Disorders, 2006, 21, 45-49.	3.9	91
138	Neuroscience, Morality. JAMA - Journal of the American Medical Association, 2006, 295, 2302.	7.4	0
139	Apolipoprotein E ɵ4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinations. Movement Disorders, 2005, 20, 989-994.	3.9	55
140	Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology, 2005, 65, 626-628.	1.1	41
141	Corpus Callosum in Neurodegenerative Diseases: Findings in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 345-351.	1.5	47
142	Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease. Neurology, 2005, 65, 1855-1856.	1.1	3
143	Value of an enzymatic assay for the determination of serum ceruloplasmin. Translational Research, 2004, 144, 294-301.	2.3	52
144	Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neuroscience Letters, 2004, 354, 177-180.	2.1	65

#	ARTICLE	IF	CITATIONS
145	Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease. <i>Stroke</i> , 2004, 35, e159-62.	2.0	124
146	Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 7-21.	0.5	24
147	Motor impairment predicts falls in specialized Alzheimer care units. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 214-8.	1.3	50
148	Parkinson's disease is associated with hippocampal atrophy. <i>Movement Disorders</i> , 2003, 18, 784-790.	3.9	294
149	Significant Linkage of Parkinson Disease to Chromosome 2q36-37. <i>American Journal of Human Genetics</i> , 2003, 72, 1053-1057.	6.2	158
150	Independent Predictors of Cognitive Decline in Healthy Elderly Persons. <i>Archives of Neurology</i> , 2002, 59, 601.	4.5	300
151	Parkinsonian syndromes and differential diagnosis. <i>Current Opinion in Neurology</i> , 2002, 15, 461-466.	3.6	12
152	Genome Screen to Identify Susceptibility Genes for Parkinson Disease in a Sample without parkin Mutations. <i>American Journal of Human Genetics</i> , 2002, 71, 124-135.	6.2	162
153	Veering in human locomotion: modulatory effect of attention. <i>Neuroscience Letters</i> , 2002, 331, 175-178.	2.1	17
154	Age at onset of Parkinson disease and apolipoprotein E genotypes. <i>American Journal of Medical Genetics Part A</i> , 2002, 107, 156-161.	2.4	61
155	Identification of parkinsonism and Parkinson's disease. <i>Drugs of Today</i> , 2002, 38, 677.	2.4	6
156	Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 208-213.	0.7	45
157	Discriminating mild parkinsonism: Methods for epidemiological research. <i>Movement Disorders</i> , 2001, 16, 33-40.	3.9	63
158	Memory Testing in Dementia: How Much Is Enough?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 1-6.	2.3	22
159	Parkinsonism and occupational exposure to pesticides. <i>Occupational and Environmental Medicine</i> , 2001, 58, 582-589.	2.8	74
160	INNOVATIVE INTERGENERATIONAL PREVENTION PROGRAMMING FOR OLDER ADULTS AND ADOLESCENTS. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 105-106.	2.6	2
161	Posterior fossa arachnoid cyst associated with an exertional tremor. <i>Movement Disorders</i> , 2000, 15, 746-749.	3.9	10
162	Dementia in Rural Primary Care Practices in Lake County, Oregon. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2000, 13, 87-92.	2.3	19

#	ARTICLE	IF	CITATIONS
163	A Small 55-Repeat MJD1 CAG Allele in a Patient with Machado-Joseph Disease and Abnormal Eye Movements. <i>European Neurology</i> , 2000, 44, 189-190.	1.4	4
164	Delays in the diagnosis of dementia: Perspectives of family caregivers. , 1999, 14, 20-26.		70
165	Apolipoprotein E $\epsilon$ 4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 437-441.	1.5	8
166	Age-related Brain Changes Associated with Motor Function in Healthy Older People. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 330-334.	2.6	96
167	Diagnosing Dementia: Perspectives of Primary Care Physicians. <i>Gerontologist</i> , The, 1999, 39, 457-464.	3.9	277
168	Analysis of the $\alpha$ -synuclein G209A mutation in familial Parkinson's disease. <i>Lancet</i> , The, 1998, 351, 37-38.	13.7	55
169	Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 181-185.	2.3	129
170	Balance in the Healthy Elderly. <i>Archives of Neurology</i> , 1997, 54, 976.	4.5	125
171	Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 584-589.	2.6	172
172	Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs. <i>Drugs and Aging</i> , 1997, 10, 367-383.	2.7	64
173	An Integrated View of Motor Behavior. <i>The Frontal Lobes and Voluntary Action</i> , by Richard Passingham. 1995. New York: Oxford University Press. 328 pp., \$35.00.. <i>Journal of the International Neuropsychological Society</i> , 1997, 3, 652-654.	1.8	0
174	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. <i>Annals of Neurology</i> , 1997, 42, 655-658.	5.3	52
175	MR imaging of Parkinson's disease with cognitive impairment and dementia. , 0, , 44-56.		0